Industry Supported Sessions

ATI Sponsored Symposium 

Friday 7 September -  07:30 - 09:00

Theme: The Challenge of Refractory Headache: Clinical Evidence for Pulsante Therapy


Why is Cluster Headache and Disabling Migraine So Difficult to Treat – The Role of the SPG

Koen Paemeleire, Belgium

Clinical Evidence for Pulsante Therapy – The EU Experience (review of CH1 & R-1 studies)

Mads C. J. Barløse


Clinical Evidence for Pulsante Therapy – Results from the US Pathway CH-2 Study

Stew Tepper

  Moderated Panel Discussion and Audience Questions


electroCore Sponsored Symposium

Friday 7 September - 13:00 - 14:30

Theme: gammaCore (nVNS) Scientific and Clinical Basis for the Treatment of Primary Headaches


Welcome and introductions


nVNS and the Trigeminal Autonomic Reflex

Celine Schroeder, Germany


Treatment of Cluster Headache with nVNS

Peter Goadsby, United Kingdom

  nVNS for the Treatment of Migraine

Cristina Tassoerelli, Italy

  Questions and answers


Eli Lilly Sponsored Symposium

Friday 7 september - 17:45 - 19:15

Theme: Challenging the Myths Around Migraine: Let’s Ask the Experts!

17:45 - 17:50

Welcome and Introductions

17:50 - 18:05

Challenging Myths About the Epidemiology and Impact of Migraine

Patricia Pozo Rosich, Spain

18:05 - 18:20

Challenging Myths About the Pathophysiology of Migraine

Peter Goadsby, United Kingdom

18:20 – 18:30



18:30 – 18:45

Challenging Myths About the Diagnosis and Treatment of Migraine

Uwe Reuter, Germany

18:45 – 19:00

Challenging Myths About New and Emerging Therapies for Migraine

David Dodick, United States

19:00 – 19:10



19:10 – 19:15 Summary and Close

David Dodick, United States

Teva Sponsored Symposium

Saturday 8 September - 07:00 - 08:30

Theme: Migraine prevention 2.0: new ways of thinking about CGRP and biologic therapy

07:00 Introduction: migraine and the challenges we hope to overcome Peter Goadsby, United Kingdom
07:10 What lies beneath? Unlocking the disease mechanisms for migraine Anthony Dickenson, United Kingdom
07:35 Migraine-specific preventive therapies: recent data Tim Jürgens, Germany

Panel Q&A

Panel, led by Prof Peter Goadsby, UK

08:25 Conclusions and next steps Peter Goadsby, United Kingdom

Novartis Sponsored Symposium

Saturday 8 September - 12:45 - 14:15

Theme: CGRP-receptor antagonism: migraine management re-invented - a promotional Satellite Symposium

12:45 – 12:55   Peter J Goadsby, United Kingdom
12:55 – 13:05


David Dodick, United States

13:05 – 13:20  

Messoud Ashina, Denmark

13:20 – 13:35  

Fayyaz Ahmed, United Kingdom

13:35 – 13:55  

Patricia Pozo Rosich, Spain and David Dodick, United States

13:55 – 14:10  


14:10 – 14:15  

 Peter J Goadsby, United Kingdom

Allergan Sponsored Symposium

Saturday 8 September - 17:30 - 19:00

Theme: Think you know BOTOX® (botulinum toxin type A)? Think again!  

17:30 Welcome and introduction Sarah Jarvis, United Kingdom
17:35 Think you know the story of BOTOX® in chronic migraine? Well, think
David Dodick, United States

Panel discussion


Manjit Matharu, United Kingdom
Patricia Pozo Rosich, Spain
Stephen Silberstein, United States
(Introduced and Moderated by
Sarah Jarvis, United Kingdom)

18:35 Real-world evidence: the next installment in the story of BOTOX®

Messoud Ashina, Denmark

18:55 Meeting Close David Dodick, United States